WallStSmart
ENLV

Enlivex Therapeutics Ltd

NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY

$0.82
-0.46% today

Updated 2026-05-01

Market cap
$197.61M
P/E ratio
0.03
P/S ratio
EPS (TTM)
$25.48
Dividend yield
52W range
$1 – $2
Volume
0.6M

Enlivex Therapeutics Ltd (ENLV) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20022003200420052006200720122013201420152016201720182019202020212022202320242025
Operating cash flow$-149000.00$-865000.00$-4.41M$-13.25M$-15.49M$-6.35M$-3.16M$-7.04M$-11.01M$-17.54M$-23.95M$-23.52M$-13.01M$-10.42M
Capital expenditures$936000.00$461000.00$418000.00$389000.00$450000.00$664000.00$0.00$2000.00$63000.00$48000.00$18000.00$2000.00$461000.00$193000.00$1.02M$1.63M$8.12M$236000.00$103000.00$68000.00
Depreciation
Stock-based comp$9000.00$254000.00$736000.00$2.62M$700000.00$408000.00$1.01M$810000.00$670000.00$2.91M$2.71M$1.95M$2.06M$1.78M
Free cash flow$-149000.00$-867000.00$-4.47M$-13.30M$-15.50M$-6.35M$-3.62M$-7.23M$-12.03M$-19.17M$-32.08M$-23.76M$-13.11M$-10.48M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash